Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation
| Autor: | John Haughney, Elizabeth Gardener, Cathal Daly, Simon Wan Yau Ming, Stephanie Wolfe, Martina Stagno d'Alcontres, David Price, Derek Skinner, Iain Small, Kevin Gruffydd-Jones, John Hamill, Joan B. Soriano |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Fixed-dose combination Rate ratio Fluticasone propionate Cohort Studies 03 medical and health sciences 0302 clinical medicine Formoterol Fumarate Internal medicine parasitic diseases medicine Humans Anti-Asthmatic Agents 030212 general & internal medicine Aged Fluticasone-Salmeterol Drug Combination business.industry Middle Aged Patient Acceptance of Health Care Asthma United Kingdom Androstadienes Drug Combinations Treatment Outcome 030228 respiratory system Ethanolamines Cohort Quality of Life Fluticasone Drug Therapy Combination Female Formoterol business medicine.drug Cohort study |
| Zdroj: | Respiratory Medicine. 129:199-206 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/j.rmed.2017.06.016 |
| Popis: | Objective Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden of this disease. Fluticasone propionate/Formoterol (FP/FOR) may be as effective as Fluticasone Salmeterol (FP/SAL). We evaluated non-inferiority of asthma control in terms of the proportion of patients free from exacerbations, and conducted a cost impact analysis. Methods This historical, matched cohort database study evaluated two treatment groups in the Optimum Patient Care Research Database in the UK: 1) an FP/FOR cohort of patients initiating treatment with FP/FOR or changing from FP/SAL to FP/FOR and; 2) an FP/SAL cohort comprising patients initiating, or remaining on FP/SAL pMDI combination therapy. The main outcome evaluated non-inferiority of effectiveness (defined as prevention of severe exacerbations, lower limit of the 95% confidence interval (CI) of the mean difference between groups in patient proportions with no exacerbations is −3.5% or higher) in patients treated with FP/FOR versus FP/SAL. Results After matching 1:3, we studied a total of 2472 patients: 618 in the FP/FOR cohort (174 patients initiated on FP/FOR and 444 patients changed to FP/FOR) and 1854 in the FP/SAL cohort (522 patients initiated FP/SAL and 1332 continued FP/SAL). The percentage of patients prescribed FP/FOR met non-inferiority as the adjusted mean difference in proportion of no severe exacerbations (95%CI) was 0.008 (−0.032, 0.047) between the two cohorts. No other significant differences were observed except acute respiratory event rates, which were lower for patients prescribed FP/FOR (rate ratio [RR] 0.82, 95% CI 0.71, 0.94). Conclusions Changing to, or initiating FP/FOR combination therapy, is associated with a non-inferior proportion of patients who are severe exacerbation-free at a lower average annual cost compared with continuing or initiating treatment with FP/SAL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect